MiGenTra GmbH
Shaheer Bardissi serves as Co-CEO at Minapharm Pharmaceuticals since April 2020 and is also an executive board member focusing on cell and gene therapy as well as immuno-oncology. In addition, Shaheer is a member of the supervisory board at ProBioGen AG and co-founder of MiGenTra GmbH, where involvement includes advisory board membership and participation in the shareholder committee. As General Manager at Bardissi Medical, Shaheer specializes in immuno-oncology and cell therapy. Shaheer's past experience includes working in immuno-oncology technology development at BioNTech SE. Educational qualifications include a PhD in Cell & Gene therapy and personalized immuno-oncology from Johannes Gutenberg University Mainz, an MS in Quantitative Management Science with a focus on healthcare data analytics and artificial intelligence from Duke University's Fuqua School of Business, an MS in Molecular Medicine from UCL, and a BS in Biomedical Sciences from King's College London.
This person is not in any teams
This person is not in any offices
MiGenTra GmbH
MiGenTra is a healthcare transforming medicines company, and a subsidiary of ProBioGen, with a focus on high quality medicines at affordable prices. The company allows for product development in the field of Biosimilars, Cell and Gene Therapies and vaccines especially for Egypt, the Middle East and Africa, and will therefore provide access to key healthcare transforming medicines, while strengthening regional and local manufacturing capacity in the region. MiGenTra combines scientific and manufacturing subject matter expertise from both contributing companies, ProBioGen and Minapharm Pharmaceuticals and is headquartered in Berlin, Germany and has access to a site in Cairo, Egypt, where the main manufacturing plant is located.